Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ4X7D
|
|||
| Drug Name |
DS-6157
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Gastrointestinal stromal tumour [ICD-11: 2B5B] | Phase 1 | [1] | |
| Company |
Daiichi Sankyo
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2] |
| G-protein coupled receptor 20 (GPR20) | Target Info | Inhibitor | [2] | |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04276415) DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST). U.S. National Institutes of Health. | |||
| REF 2 | Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.